Anemia of Cancer in Intermediate-Grade Non-Hodgkinʼs Lymphoma

Anemia as a useful biomarker in patients with diffuse large B‐cell lymphoma treated with R‐CHOP immunochemotherapy

“…Among patients with follicular lymphoma, a representative indolent lymphoma, Hb < 12.0 g/dL was found to be an independent prognostic factor and has become one of the factors of the FLIPI and FLIPI 2 . In a retrospective evaluation of 591 patients with intermediate‐grade NHL, Morrow et al . reported that baseline CIA (Hb < 12.0 g/dL) was associated with poor patient characteristics and a predictor of non‐responsiveness to chemotherapy.…”

“…(5,6) Among patients with follicular lymphoma, a representative indolent lymphoma, Hb < 12.0 g ⁄ dL was found to be an independent prognostic factor and has become one of the factors of the FLIPI (7) and FLIPI 2. (8) In a retrospective evaluation of 591 patients with intermediate-grade NHL, Morrow et al (9) reported that baseline CIA (Hb < 12.0 g ⁄ dL) was associated with poor patient characteristics and a predictor of non-responsiveness to chemotherapy. In a previous French study among 2210 patients with high-grade NHL treated with intensive induction chemotherapeutic regimen ACVB (doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone), the baseline Hb level <8.5 g ⁄ dL was an independent predictive factor for early death.…”

“…In a previous French study among 2210 patients with high-grade NHL treated with intensive induction chemotherapeutic regimen ACVB (doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone), the baseline Hb level <8.5 g ⁄ dL was an independent predictive factor for early death. (10).Although those studies (5,(7)(8)(9)(10) support the prognostic value of CIA in patients with NHL, they mainly included patients with heterogeneous subtypes of NHLs in the pre-rituximab era. In addition, the clinical significance of TIA, particularly CTIA, has not been studied in patients with NHL.…”

“…Although those studies (5,(7)(8)(9)(10) support the prognostic value of CIA in patients with NHL, they mainly included patients with heterogeneous subtypes of NHLs in the pre-rituximab era. In addition, the clinical significance of TIA, particularly CTIA, has not been studied in patients with NHL.…”